Published in Lab Law Weekly, April 22nd, 2005
The exclusive license agreement provides CABG Medical (CABG) with access to Angiotech's pioneering technology to treat restenosis and proliferative disease through the local delivery of the drug paclitaxel, and to Angiotech's extensive intellectual property portfolio related to this technology. CABG Medical will employ Angiotech's technology in the field of coronary artery bypass grafts.
In connection with the license agreement, Angiotech will receive a warrant to purchase 1,262,823 shares of CABG Medical's common stock, exercisable at $0.01 per...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Law Weekly